MPE newsletter

MPE activities

Myeloma Patients Europe (MPE) held the first Myeloma CAB

Based on the proven CML Advocates Network and ECAB model implemented by the HIV patient community and European AIDS Treatment Group (EATG), MPE held the first myeloma CAB from 11 to 13 May in Warsaw, Poland, to promote best-in-class myeloma research as well as the harmonisation of good clinical practice, standard of care and access to best available myeloma therapies and diagnostic tools. A range of topics were discussed in these successful meetings between sponsors and advocates such as innovative therapies, access to myeloma drugs in Europe and patient involvement in medicines research and development.

Survey on myeloma patient information needs

Myeloma Patients Europe (MPE) and Amgen are launching a survey for European myeloma patients to understand their information needs. If you are a myeloma patient living in the UK, and have received at least one prior treatment or are currently on your first treatment, MPE would be very grateful if you would take the time to complete the anonymous survey. The survey will be run in 12 European countries, however, at this stage we need responses from UK patients only.

 

 

MPE webinar on CAR-T cell treatment in myeloma

MPE held a webinar on CAR-T cell treatment with the aim of providing an overview of CAR-T cell treatment in myeloma and to discuss some of the advantages and challenges the myeloma community faces in bringing this treatment to market. The talk was given by Dr Matteo Carrabba, Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan (Italy).

MPE members’ activities

Myeloma month in Armenia

On the occasion of the myeloma month in March, the MPE Armenian member, the Armenian Hematology Association, along with the Young branch of the Armenian Hematology Association held different talks aimed to share the latest updates in myeloma in 2018.
For the first time, these organisations held an interdisciplinary discussion to cover the different consequences that myeloma can have for patients. A pathologist, a nephrologist, a radiotherapist and an expert in osteoporosis were invited to the discussion which covered a range of topics such as myeloma pathogenesis and clinical aspects, the management of plasmocytoma treatment, myeloma in elderly patients and mobility problems in myeloma patients.
 
If you are an MPE member and you would like to share your activities in this e-bulleting, please contact Ana Vallejo: vallejo@mpeurope.org.

News

Myeloma sessions at EHA 2019

The European Hematology Association (EHA) Annual Meeting is the most important congress of haematology in Europe in which latest developments and cutting-edge research in haematological diseases will be discussed. If you are a myeloma patient advocate attending this congress, find in this link the myeloma and advocacy sessions that will be held at EHA 2019 in Amsterdam, The Netherlands.

Read more…
 

ASCO 2019 myeloma highlights

More than 40,000 people attended the American Society of Clinical Oncology (ASCO) Annual Meeting (ASCO 2019) which was held in Chicago from 31 May until 4 June. This meeting brings together oncology and haematology professionals from across the globe to discuss the latest scientific and treatment developments in the field.
A number of myeloma topics were presented in this important scientific meeting. The most important updates are outlined in the link below.

 

Read more…
 

Takeda announces discontinuation of the phase 3 clinical trial TOURMALINE-AL1 in AL amyloidosis

The pharmaceutical company Takeda announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory AL amyloidosis did not meet the first of two primary endpoints.
Treatment with ixazomib in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared to physician’s choice of standard of care regimens. As a result of this analysis, Takeda has decided to discontinue the trial. Read more information here.

 
 
 
 
 

Copyright © 2019 Myeloma Patients Europe, All rights reserved.
Myeloma Patients Europe AISBL newsletter subscription

Our mailing address is:

Myeloma Patients Europe

Avenue Louise 149/24 1050 Brussels Belgium

Brussels 1050

Belgium

Add us to your address book

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

Podijeli

Zagreb, HR
20°C
vedro

Hrvatska udruga leukemija i limfomi
predsjednik Dražen Vincek
Trg hrvatskih velikana 2/ll
10 000 Zagreb
GSM: +385 (0)91 4873 561
TEL: +385 (0)1 4873 561
e-mail: udruga.hull.zagreb@gmail.com
Web adresa: www.hull.hr
IBAN: HR 36 2340 0091 1100 4711 4
SWIFT CODE: PBZGHR2X

Važni datumi

[spiffy-minical]

Health through Knowledge

Klasa optimist

Istaknuti sponzori HULL-a